Q32 Bio (QTTB) Insider Mark Iwicki Buys 9,810 Shares

On June 12, 2026, Mark Iwicki bought 9,810 shares of QTTB. This insider purchase was not part of a pre-planned trading program. The stock was trading at $12.75 at the time of the transaction.

Insider Buying and Selling at Q32 Bio Inc.

Several insiders, including Mark Iwicki, Kathleen Laporte, David Grayzel, Arthur Tzianabos, Sven Ante Lundberg, and Diyong Xu, each purchased 9,810 shares of QTTB on June 12, 2026. These transactions were not pre-planned.

Other Institutional Activity in QTTB

Opaleye Management Inc. significantly increased its position by 1,042,865 shares, ending with 1,256,228 shares valued at approximately $8.06 million. OrbiMed Advisors LLC, Atlas Venture Life Science Advisors, LLC, and Carlyle Group Inc. maintained their holdings with no changes, holding 2,252,987 shares, 2,092,106 shares, and 1,102,741 shares, respectively. Acorn Capital Advisors, LLC, however, reduced its stake by 178,373 shares to 315,052 shares, valued at about $2.02 million.

Q32 Bio Inc. Stock Up 21.0%

Shares of QTTB are currently trading near $12.75. Although specific financial metrics such as market cap and P/E ratio are not available, the stock's activity reflects interest from both insiders and institutional investors.

Analysts Set New Price Targets

On May 22, 2026, Mizuho initiated coverage on QTTB with a 'buy' rating and a $14.00 price target. HC Wainwright & Co. reiterated its 'buy' rating on May 5, 2026, with a target of $13.00. The consensus among analysts suggests a positive outlook, with a mean target price reflecting potential upside.

Bottom Line

Mark Iwicki's recent purchase of QTTB shares highlights insider confidence in the company. The stock is drawing attention from both insiders and analysts, with several 'buy' ratings suggesting optimism. While 13F filings and insider transactions offer a glimpse into investor sentiment, they reflect past actions and do not necessarily indicate future performance.